UB-VV400 with rapamycin for large B-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests an experimental treatment called UB-VV400 given with another drug, rapamycin, for people with large B-cell lymphoma that has not responded to standard therapy. The treatment targets a protein called CD22 on lymphoma cells and may help your immune system fight the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a large B-cell lymphoma that has not responded to treatment or has come back.
- Your lymphoma cells show a protein called CD22.
- You are generally well and able to care for yourself (ECOG score 0 or 1).
- Your organs are working well enough, and you do not have serious infections or other illnesses.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new therapy called UB-VV111, alone or with rapamycin, in people with certain types of lymphoma or leukemia that have come back or not responded to treatment. The goal is to see if it's safe and effective.
This study tests an experimental drug for people with B-cell non-Hodgkin lymphoma (a type of blood cancer) that has come back or hasn't responded to standard treatments. The goal is to see if the drug is safe and can shrink the cancer.
This trial tests a new combination therapy (UB-VV400 plus rapamycin) for people with B-cell cancers that have come back or not responded to previous treatment. It aims to see if this approach is safe and effective.
This trial tests an investigational cell therapy called UB-VV500 combined with rapamycin, a drug that may help the therapy work better. It is for people whose multiple myeloma has come back or stopped responding to prior treatments. The goal is to see if this combination is safe and effective.
This trial tests a new combination of targeted drugs called ViPOR for people with aggressive B-cell lymphoma that has come back or not responded to previous treatment. The goal is to see if this treatment can help when standard therapies haven't worked.
This trial tests a combination of two immunotherapy drugs (rimegepant and glofitamab) plus a special cell therapy called CD19 CAR-T for people with large B-cell lymphoma that has not responded to or has returned after previous treatment. The goal is to see if this combination can better control the lymphoma and improve outcomes.
Hear when a new High-grade B-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.